期刊
KIDNEY INTERNATIONAL
卷 77, 期 9, 页码 755-757出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ki.2010.26
关键词
-
Biomarkers hold promise for personalizing renal cancer care by potentially identifying patients most likely to benefit from novel therapies. Porta and colleagues report that among subjects with advanced renal-cell carcinoma receiving sunitinib treatment, those with above-normal levels of the circulating biomarkers vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin displayed significantly lower progression-free survival times. This Commentary reviews the current status of these biomarkers with respect to methodological issues, specificity, and biological plausibility. Kidney International (2010) 77, 755-757. doi: 10.1038/ki.2010.26
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据